Tyrosine kinase inhibitorFDA-approvedSecond-line
Mektovi
Generic name: binimetinib
How it works
Binimetinib blocks the MEK1 and MEK2 enzymes, which are involved in the MAPK signaling pathway.
Cancer types
Colorectal Cancer— BRAF V600E-mutated
Efficacy
In clinical trials, binimetinib improved response rates and overall survival in patients with metastatic colorectal cancer harboring the BRAF V600E mutation.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.